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Pumpkin crude extract (PCE) was extracted from pumpkin powder with water and 95%
ethanol at 60C. Several components were isolated and further purified by solvents puri-
fication and dialysis as well as column chromatography. The anti-diabetic activities of the
hypoglycemic components extracted from pumpkin were identified using diabetic model
mice which were induced by alloxan intraperitoneal injection. The diabetic mice were
treated with pumpkin extracts by intraperitoneal injection at dosages of 100, 200 and
400 mg/kg body weight. Blood samples for glucose assays were taken from the diabetic
mice before injection and 4, 7 and 11 hours after injection. The results showed that the
blood glucose levels in the diabetic mice were significantly reduced by PCE-C from
15.32  4.38 mM to 5.77  1.46 mM ( p < 0.001) in 7 hours. PCE-C was further purified by
deproteinization, dialysis and Sephadex G-100 column chromatography and a fraction as
PCE-F was collected. Seven hours after PCE-F injection at a dosage of 200 mg/kg body
weight, blood glucose levels dropped significantly from 15.90  3.21 mM to 7.19  2.54 mM
( p < 0.01). PCE-F was identified by gas chromatography as a polysaccharide consisting of
heterogeneous monosaccharides, such as glucose, galactose, arabinose and rhamnose.
Copyright ª 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. Open access under CC BY-NC-ND license.1. Introduction hypoglycemic agents (factors that enhance the activity of theDiabetes mellitus is a chronic metabolic disorder character-
ized by a high level of glucose in the blood due to the non-
secretion of insulin or insulin insensitivity. Diabetes mellitus
is considered a common, growing, serious, costly, and
potentially preventable public health problem. The number of
people with diabetes is estimated to increase from 117million
in 2000 to 366million in 2030. Individuals, families and nations
will continue to bear the economic burden of healthcare due
to the prevalence of diabetes [1]. Current therapeutic options
include lifestyle adjustments (exercise and diet), oralces, China Ji Liang Unive
-J. Zhang).
ministration, Taiwan. Pubb-cells) [2,3], inhibitors of a-glucosidase at the level of the
small intestine [4,5], factors that enhance peripheral insulin
sensitivity [6,7], and insulin treatment [8,9]. However, the
drugs used to treat this disorder are expensive, have side ef-
fects or contraindications. Dietary intervention, particularly
the use of traditional food and medicine derived from natural
sources, is amainstay in themanagement of diabetesmellitus
[10]. Natural plant-derived drugs provide several potential
options for the control of diabetes [11,12]. These plant-derived
components may be less toxic and have fewer side effects
than synthetic agents [13].rsity, Hangzhou, Zhejiang, PR China.
lished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
j o u r n a l o f f o o d and d ru g an a l y s i s 2 1 ( 2 0 1 3 ) 1 8 4e1 8 9 185Pumpkin (Cucurbita moschata Duch, a member of the
Cucurbitaceae family) consists of succulent coarse vine and
numerous seeds. It is a popular traditional healthy food with
hypoglycemic and anti-diabetic activities. It has been reported
that Cucurbita species exhibit diverse pharmacological activ-
ities [1], including antioxidant activities, antimicrobial and
hypoglycemic effects [14e21]. Li et al reported that protein-
bound polysaccharides extracted from pumpkin significantly
increased levels of serum insulin, reduced blood glucose levels
and improved glucose tolerance [22,23]. Zhu et al found that
pumpkin polysaccharides can decrease the blood glucose
level of diabetic rats, enhance the activity of superoxide dis-
mutase, reduce the production of malondialdehyde and ni-
trogenmonoxide, and improve the ultra-structural features of
islet cells [24].
In this study, we isolated and purified the most effective
hypoglycemic components from pumpkin, investigated their
anti-diabetic activities using alloxan-induced diabetic mice,
and analyzed the main monosaccharide composition of the
polysaccharides in the pumpkin extracts.2. Methods
2.1. Plant materials and chemicals
Fresh and uniformly shaped pumpkins were selected from a
commercial pumpkin farm in Wuxi (Jiangsu Province, China).
The fresh pumpkin was peeled, the seeds were removed, and
the pumpkin sliced into pieces measuring 0.5  2.0  5.0 cm.
The slices were sun dried and ground into powder.
Alloxan was purchased from Sigma Chemical Co. (St Louis,
MO, USA). A one-touch glucometer was purchased fromRoche
Diagnostics GmbH (Mannheim, Germany) for the analysis of
blood glucose (BG). All other chemicals were of analytical
grade.
2.2. Animals
Young adult (6e7 weeks, 20e25 g, male and female) Kunming
mice were purchased from Wuxi Atom Medicine Research
Institute (Jiangsu, China). The mice were housed in cages on a
12-hour lightedark cycle with accessibility to food and tap
water. Temperature and humidity in the cages were held at
25  2C and 55e60%, respectively.
2.3. Extraction of hypoglycemic components from
pumpkin powder
Pumpkin powder was mixed with distilled water at a ratio of
1:3 (w/w) at 60C for 2 hours and then centrifuged at 3000 rpm
for 20 minutes. The supernatant was collected as a water-
soluble extract while the sediment was mixed with 95%
alcohol at a ratio of 1:3 (w/w) for 48 hours at 4C followed by
centrifugation at 3000 rpm for 10 minutes. The sediment was
discarded while the supernatant, the alcohol-soluble extract,
was mixed with the previously collected water-soluble
extract. The mixture of the water-soluble and alcohol-
soluble extracts was named “pumpkin crude extract” (PCE).
The PCE was further extracted 3e5 times with ether at 20C.The ether phase was collected and rotary evaporated and the
collected residue was named PCE-A. The aqueous phase was
further extracted 3e5 times with n-butyl alcohol at 20C. The
n-butyl alcohol phase was collected and rotary evaporated
and the collected residue was named PCE-B. The aqueous
phasewasmixedwith 95% alcohol at a ratio of 1:2 (w/w) at 4C
and the collected precipitate was named PCE-C while the
alcohol extract was evaporated and the collected residue was
named PCE-D.
2.4. Purification of effective components
To remove proteins and some low molecular weight com-
pounds from PCE-C, Sevag reagent [25] and dialysis were
employed successively. The crude polysaccharide solution
was rotary evaporated under vacuum at a temperature below
50C before being dried in a vacuumoven for 1week. The dried
crude polysaccharide powder was named PCE-E; it was light
yellow and easy to dissolve in water.
PCE-E was purified over a Sephadex G-100 (Amersham
Pharmacia, Sweden) column (108 cm  1.5 cm). Fifty mM of
sodium phosphate buffer was used as the mobile phase at a
flow rate of 10 mL/h. Fractions were collected and the poly-
saccharide content was assayed by the phenol-sulfuric acid
method [26] using glucose as the standard. The fractions
containing polysaccharide were dialyzed, concentrated,
precipitated with alcohol, and lyophilized to obtain PCE-F and
PCE-G.
2.5. Quantification of polysaccharides in PCE-F
The content of carbohydrates in the hypoglycemic compo-
nents from pumpkin was measured by the phenol-sulfuric
acid method. The polysaccharide content was calculated
using the following formula:
Polysaccharidecontentð%Þ¼ðmeasuredamountof
carbohydrates=weightof sampleÞ
100%
The protein content of the hypoglycemic components was
determined by the Bradford method using bovine serum al-
bumin as the standard [27].
2.6. Determination of monosaccharide composition of
PCE-F by gas chromatography
The main monosaccharide composition of the hypoglycemic
components from pumpkin was determined by gas chroma-
tography. Ten milligrams of sample was hydrolyzed in 10 mL
of 2 M trifluoroacetic acid at 105C for 2 hours and mono-
saccharides therein reacted with trimethylsilylating reagent.
The trimethylsilylated derivatives were loaded onto an HP-5
capillary column and monitored by a flame ionization detec-
tor. The following program was adopted for gas chromatog-
raphy analysis: injection temperature, 230C; detector
temperature, 230C; column temperature was programmed to
increase from 130C to 180C at 5C/min, hold at 180C for 5
minutes, increase to 220C at 5C/min and finally hold at 220C
for 3 minutes. Nitrogen was used as the carrier gas and
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nose, galactose, glucose, mannose, xylose, and fructose were
used as standards. Inositol was used as the internal standard.
2.7. Preliminary screening for the components with
hypoglycemic effects
The mice were segregated into the following groups: normal
control group, hyperglycemic model group, and the group
treated with various components from pumpkin (PCE group).
The PCE group was further divided into three dosage sub-
groups: 10 mice in each subgroup were injected with PCE at
dosages of 100, 200 and 400 mg/kg BW. Mice were fasted
overnight and diabetes was induced by a rapid intravenous
injection of alloxan (200mg/kg BW) freshly dissolved in saline.
The mice were then given 5% glucose in drinking water
overnight to prevent hypoglycemia. Alloxan-diabetic mice
were allowed free access to food and water until further
experiment. After 72 hours, mice with blood glucose levels
greater than 11.3 mM were selected as the alloxan-induced
diabetic mice [28]. The mice in the normal control group and
hyperglycemic model group were intraperitoneally injected
with the same volume of normal saline instead of PCE. During
the experimental period, the mice had free access to food and
water. BG was measured by drawing blood from the tail veins
of the mice at 4, 7 and 11 hours after intraperitoneal injection.
2.8. Experimental design
The mice were randomly separated into 20 groups with 10
animals in each group. Groups 1e8 were normal mice. Mice in
Group 1, the control group, were injected with saline (0.86%
NaCl). The mice in Groups 2, 3 and 4 were injected with 100,
200 and 400 mg/kg BW of PCE, respectively. The mice in
Groups 5, 6, 7 and 8were injectedwith 200mg/kg BWof PCE-A,
-B, -C and -D, respectively. The other groups comprised mice
with alloxan-induced diabetes (Groups 9e20). The mice in
Group 9, the hyperglycemic model group, were injected with
0.86% NaCl only. The mice in Group 10, the positive control,
were injected with the Xiaoke pill, a Chinese medicine widely
used in the clinical treatment of diabetes in China, at 750 mg/Table 1 e Effects of PCE on BG concentrations (mM) in normal
Group PCE dosage
(mg/kg BW)
0
Control group 0 5.07  0.45
Model group 0 12.85  2.92
Positive control group 750 12.36  2.72
Normal group (PCE) 100 4.70  0.42
200 5.50  0.85
400 4.82  0.69
DM group (PCE) 100 12.46  2.86
200 13.01  3.67
400 13.12  3.45
a Compared with the hyperglycemic model group, n ¼ 10, mean  SE, p
b compared with the control group, n ¼ 10, mean  SE, p < 0.05.
c compared with the control group, n ¼ 10, mean  SE, p < 0.01.kg BW in 0.86% NaCl. The mice in Groups 11, 12 and 13 were
injected with PCE at dosages of 100, 200 and 400 mg/kg BW,
respectively. The mice in Groups 14, 15, 16, 17, 18, 19 and 20
were injectedwith 200mg/kg BWof PCE-A, -B, -C, -D, -E, -F and
-G, respectively. Blood samples were taken from the tail vein
of the mice before and 4, 7 and 11 hours after intraperitoneal
injection, and BG was measured using the one-touch
glucometer.
2.9. Statistical analysis
Data are presented as x  SD from multiple experiments.
Statistical analyses were performed using Statview (version
1.30; Abacus Concepts, Inc., Berkeley, CA, USA). Variations
within groups of animals were determined by analysis of
variance and t test. A probability value of p < 0.05 was
considered significant.3. Results
3.1. Preliminary screening of the components with
hypoglycemic effects
Before intraperitoneal injection and 4, 7 and 11 hours after
intraperitoneal injection of PCE, the BG concentrations in mM
in the diabetic mice decreased to different levels (Table 1).
Compared to the BG concentrations of the mice in the hy-
perglycemic model group, the BG concentrations in both the
normal and diabetic groups injected with 200 and 400 mg/kg
BW of PCE decreased significantly, especially 7 hours after
intraperitoneal injection. At 7 and 11 hours after injection
with 200 mg/kg BW of PCE, the BG concentrations in the dia-
betic mice were significantly lower ( p < 0.05 at both times)
than those in the hyperglycemic model group. At the same
dosage of 200 mg/kg BW, the BG concentrations at 7 and 11
hours after treatment in the normal group were significantly
lower ( p < 0.01 and <0.05, respectively) than those in the
control group. The BG levels of the diabeticmice in the 200mg/
kg BW PCE group were 55.25% lower than those in the hy-
perglycemic model group, while the BG levels in the positivemice and alloxan-induced diabetic mice.
Time after intraperitoneal injection (h)
4 7 11
5.05  0.32 5.05  0.49 5.02  0.35
13.32  2.87 13.15  2.59 13.18  3.04
10.18  2.76 9.02  2.54a 9.88  2.97
4.54  0.78 4.12  0.59 4.09  0.46
4.94  0.97 3.92  0.88c 3.96  0.79b
4.53  0.87 4.08  0.59b 4.11  0.54
12.02  3.11 11.27  2.77 11.32  2.57
10.42  3.15 8.47  2.14a 8.64  2.52a
11.24  3.02 9.25  2.73a 9.97  2.86
< 0.05.
Fig. 1 e Chromatogram of PCE-E using a Sephadex G-100
gel column. Fractions were analyzed by the phenol-sulfuric
acid reaction to estimate the sugar content (490 nm).
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cemic model group at 7 hours after intraperitoneal injection.
The results indicated that PCE has a dose-dependent BG-
lowering activity in diabetic mice.
3.2. BG-lowering effects of PCEs in diabetic mice
The BG concentrations of the diabetic mice decreased to
different extents before and 7 hours and 11 hours after
intraperitoneal injection of 200 mg/kg BW of PCE-A, PCE-B,
PCE-C and PCE-D (Table 2). These results indicated that PCE-A
and PCE-B had significant effects on reducing the BG levels of
normal mice from 5.77  1.02 mM to 3.88  0.48 mM ( p < 0.01)
and from 5.88  0.72 mM to 3.98  0.78 mM ( p < 0.01),
respectively. However, there was no significant difference in
BG levels before and after PCE-A and PCE-B treatment in the
alloxan-diabetic mice group. The BG levels in the normal and
alloxan-diabetic mice treated with PCE-D showed no signifi-
cant difference ( p> 0.05), indicating that PCE-D does not have
any BG-lowering effect on the tested mice.
PCE-C showed a BG-lowering effect on normal mice. The
BG level decreased significantly ( p< 0.05) from 5.39 0.75mM
before PCE-C treatment to 4.40  0.84 mM 7 hours after PCE-C
injection. However, no significant decrease was observed 11
hours after PCE-C treatment. For alloxan-diabetic mice, PCE-C
treatment resulted in a significant decrease ( p < 0.001) in BG
level from 15.32  4.38 mM before PCE-C injection to
5.77  1.46 mM 7 hours after PCE-C treatment. The hypogly-
cemic effect of PCE-C may not be due to the stimulation of
insulin secretion but by other pathways.
3.3. Purification of PCE-C by column chromatography
PCE-C was separated from PCE by partition with different
organic solvents with a yield of 13.6%, and its crude protein
content was 2.37%. PCE-E was obtained after protein removal
by the Sevag reagent and the protein content decreased to
0.31%. PCE-F and PCE-G were two fractions of PCE-E separated
by column chromatography using Sephadex G-100 as the
stationary phase. The yield of PCE-F was 57.48% while the
yield of PCE-G was 34.18% (Fig. 1). These two fractions wereTable 2 e Effects of PCE-A, PCE-B, PCE-C and PCE-D on BG
levels (mM) in normal and alloxan-induced diabeticmice.
Group Time after PCE treatment (h)
0 7 11
Normal PCE-A 5.77  1.02 4.30  0.77a 3.88  0.48b
PCE-B 5.88  0.72 3.98  0.78b 4.29  0.79a
PCE-C 5.39  0.75 4.40  0.84 a 4.61  0.92
PCE-D 5.76  0.66 5.70  0.72 5.24  0.81
Diabetic PCE-A 15.40  4.76 14.62  3.04 15.63  3.32
PCE-B 16.03  4.16 13.12  2.87 13.33  3.68
PCE-C 15.32  4.38 5.77  1.46c 5.80  0.94c
PCE-D 13.50  3.87 12.76  2.81 13.04  2.97
a p < 0.05, compared to 0 h PCE treatment, n ¼ 10, mean  SE.
b p < 0.01, compared to 0 h PCE treatment, n ¼ 10, mean  SE.
c p < 0.001, compared to 0 h PCE treatment, n ¼ 10, mean  SE.both light yellow powders and easy to dissolve in water but
not in organic solvents such as acetone, ether, chloroform or
butanol. The reactions of the two PCE subfractions with the
phenol-sulfuric acid reagent were positive while the ninhy-
drin tests were negative, which indicated that these two
fractions did not contain any amino acids or proteins.
Furthermore, the reactions of the two PCE subfractions with
the iodine-potassium iodide reagent were negative, indicating
that they were non-starch polysaccharides.
3.4. BG-lowering effects of PCE-E, PCE-F and PCE-G
Before and 7 hours and 11 hours after intraperitoneal injection
of 200 mg/kg BW of PCE-E, PCE-F and PCE-G, the BG concen-
trations of the diabetic mice were measured (Table 3). The
results indicated that PCE-E exerted a significant effect on
diabetic mice. The BG in diabetic mice decreased from
16.01  3.51 mM (before PCE-E treatment) to 7.64  2.32 mM
( p < 0.001) 11 hours after PCE-E treatment, which indicates
that PCE-E had a BG-lowering effect on diabetic mice.
There was no significant difference in the BG levels of
diabetic mice before PCE-G treatment and 11 hours after PCE-
G treatment, indicating that PCE-G did not have any BG-
lowering effect. BG levels decreased significantly from
15.90  3.21 mM (before PCE-F treatment) to 7.19  2.54 mM 7
hours after PCE-F treatment. The BG level was maintained at
8.23 2.26mM 11 hours after PCE-F treatment, indicating that
PCE-F not only had a BG-lowering effect but also a BG-
maintaining effect on diabetic mice.Table 3 e Effects of PCE-E, PCE-F and PCE-G on BG levels
(mM) in alloxan-induced diabetic mice.
Group Time after PCE treatment (h)
0 7 11
PCE-E 16.15  3.43 8.04  2.46b 7.91  2.38b
PCE-F 15.90  3.21 7.19  2.54a 8.23  2.26a
PCE-G 17.65  3.12 14.55  3.24 13.67  2.86
a p < 0.01, compared to 0 h PCE treatment, n ¼ 10, mean  SE.
b p < 0.001, compared to 0 h PCE treatment, n ¼ 10, mean  SE.
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Purified PCE-F was hydrolyzed by trifluoroacetic acid into
monosaccharides, which were further trimethylsilylated for
gas chromatography analysis. The results are shown in Fig. 2.
Four monosaccharidesdglucose, galactose, arabinose and
rhamnosedwere identified with a molar ratio of 2.0:1.0:1.5:2.5
(with galactose as the reference).4. Discussion
In the present study, the anti-diabetic potential of pumpkin
polysaccharides to alloxan-induced diabetic mice was investi-
gated. Alloxan is a known compound that induces insulin
deficiency in most animal models with some remarkable sim-
ilarities tohuman insulin-dependentdiabetesmellitus [29]. The
diabetogenic agent is a hydrophilic and chemically unstable
pyrimidinederivative that is toxic topancreaticb-cells [30]. This
compound, due to its similarity in three-dimensional structure
to glucose molecules, undergoes uptake by pancreatic b-cells
via low-affinity GLUT2 glucose transporters in the plasma
membrane [31,32]. There is a possibility for the survival of a few
b-cells and thishasbeenshownbyseveral researchgroupswho
observed anti-hyperglycemic activity with oral hypoglycemic
agents in alloxan-induced diabetic rats [33,34].
The fundamental mechanism underlying hyperglycemia
in diabetes mellitus involves overproduction of glucose by
excessive hepatic glycogenolysis and gluconeogenesis, and
decreased utilization of glucose by tissues. The pathogenesis
of diabetes always involves disturbances in carbohydrate, fat
and protein metabolism. These complex multifactorial
metabolic changes often lead to functional impairment of
many organs, most importantly that of the cardiovascular
system, in both types of diabetes [35]. Our results indicated
that PCE significantly reduced BG concentrations in diabetic
mice ( p < 0.05). Compared to the normal and diabetic groups,
the BG-lowering effect of PCE at a dosage of 200mg/kg BWwas
stronger than that of 100 or 400 mg/kg BW. In normal mice,Fig. 2 e Gas chromatogram of the monosaccharide
composition of PCE-F. (A) The sugar standards. (B) The
tested PCE-F. 1. Rhamnose 2. Arabinose 3. Xylose 4.
Mannose 5. Glucose 6. Galactose 7. Inositol.PCE-C treatment caused their BG level to drop significantly 7
hours after treatment ( p < 0.05), but no significant difference
was observed 11 hours after treatment. In alloxan-diabetic
mice, PCE-C treatment significantly decreased BG level 7
hours after treatment. Based on the results described above,
we propose that the major function of PCE-C is not to stimu-
late b-cells in the islets of Langerhans to increase insulin
secretion, but rather restore the islets of Langerhans, repairing
impaired islets or act as an insulin sensitizer to enhance in-
sulin action by improving the insulin sensitivity of target tis-
sues such as the liver, muscle and adipose tissue. Pumpkin
polysaccharides may also play an important role in the re-
covery of liver function and glucose utilization, which is
similar to the activity of polysaccharides found in Chinese
medicine, such as Hedysarum polybotrys polysaccharides and
Opuntia dillenii polysaccharides [36,37].
Based on this study’s results, further chemical and phar-
macological investigations should be carried out to evaluate
the mechanisms of the anti-diabetic activity of pumpkin
polysaccharides.
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